MPLT (MapLight Therapeutics) Insider Ownership: 6.78 % (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $12.91
! 2 Warning Signs
View Full Analysis

What is MapLight Therapeutics Insider Ownership?

MapLight Therapeutics MPLT -0.04% 14 Insider Ownership is 6.78 % as of Aug. 06, 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MapLight Therapeutics's insider ownership is 6.78%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MapLight Therapeutics's Institutional Ownership is 54.71%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MapLight Therapeutics's Float Percentage Of Total Shares Outstanding is 48.51%.

MapLight Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Insider Ownership Chart

MapLight Therapeutics Historical Data

The historical data trend for MapLight Therapeutics can be seen below:

2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 2.08 1.97 8.62 8.84 7.26 7.44 6.78
MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 6.78 % mean?
MapLight Therapeutics (MPLT) has a Insider Ownership of 6.78 % as of Aug. 06, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MapLight Therapeutics and its competitors.
Is MapLight Therapeutics' Insider Ownership too high?
MapLight Therapeutics' current Insider Ownership is 6.78 %. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Insider Ownership compare to SRPT and ZYME?
MapLight Therapeutics' Insider Ownership of 6.78 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Insider Ownership is 6.78 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Insider Ownership of 6.78 %. The current Insider Ownership is 6.78 %. MapLight Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Insider Ownership is 6.78 % as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.91
Price